Non-Coding RNAs and Endometrial Cancer
Abstract
:1. Introduction
2. Endometrial Cancer: Overview
Long Non-Coding RNAs: General Introduction
3. Competing Endogenous RNAs, miRNA, lncRNA Profiling Regulation and Cancer
4. Regulation of Cell Growth by Long Non-Coding RNAs in Endometrioid Endometrial Adenocarcinoma
5. Long Intergenic Non-Protein Coding RNA, Regulator of Reprogramming and Endometrioid Endometrial Adenocarcinoma
6. Micro IRNA in Endometrioid Endometrial Adenocarcinoma
Micro RNA as a Marker and Promoter of Tumor Aggression in EEC
7. Conclusions
Conflicts of Interest
References
- Kapranov, P.; Cheng, J.; Dike, S.; Nix, D.A.; Duttagupta, R.; Willingham, A.T.; Stadler, P.F.; Hertel, J.; Hackermüller, J.; Hofacker, I.L.; et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007, 316, 1484–1488. [Google Scholar] [CrossRef] [PubMed]
- Ma, L.; Bajic, V.B.; Zhang, Z. On the classification of long non-coding RNAs. RNA Biol. 2013, 10, 925–933. [Google Scholar] [CrossRef] [PubMed]
- Ling, H.; Vincent, K.; Pichler, M.; Fodde, R.; Berindan-Neagoe, I.; Slack, F.J.; Calin, G.A. Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene 2015, 34, 5003–5011. [Google Scholar] [CrossRef] [PubMed]
- Ponjavic, J.; Ponting, C.P.; Lunter, G. Functionality or transcriptional noise? Evidence for selection within long noncoding RNAs. Genome Res. 2007, 17, 556–565. [Google Scholar] [CrossRef] [PubMed]
- Wang, K.C.; Chang, H.Y. Molecular mechanisms of long noncoding RNAs. Mol. Cell 2011, 43, 904–914. [Google Scholar] [CrossRef] [PubMed]
- Smolle, M.A.; Bullock, M.D.; Ling, H.; Pichler, M.; Haybaeck, J. Long Non-Coding RNAs in Endometrial Carcinoma. Int. J. Mol. Sci. 2015, 16, 26463–26472. [Google Scholar] [CrossRef] [PubMed]
- Mattick, J.S.; Amaral, P.P.; Dinger, M.E.; Mercer, T.R.; Mehler, M.F. RNA regulation of epigenetic processes. Bioessays 2009, 31, 51–59. [Google Scholar] [CrossRef] [PubMed]
- Cheetham, S.W.; Gruhl, F.; Mattick, J.S.; Dinger, M.E. Long noncoding RNAs and the genetics of cancer. Br. J. Cancer 2013, 108, 2419–2425. [Google Scholar] [CrossRef] [PubMed]
- Lv, Z.; Xu, Q.; Yuan, Y. A systematic review and meta-analysis of the association between long non-coding RNA polymorphisms and cancer risk. Rev. Mutat. Res. 2017, 771, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Tsikouras, P.; Bouchlariotou, S.; Vrachnis, N.; Dafopoulos, A.; Galazios, G.; Csorba, R.; von Tempelhoff, G.F. Endometrial cancer: Molecular and therapeutic aspects. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013, 169, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5–29. [Google Scholar] [CrossRef] [PubMed]
- Rose, P.G. Endometrial carcinoma. N. Engl. J. Med. 1996, 335, 640–649. [Google Scholar] [CrossRef] [PubMed]
- Sherman, M.E.; Sturgeon, S.; Brinton, L.; Kurman, R.J. Endometrial cancer chemoprevention: Implications of diverse pathways of carcinogenesis. J. Cell. Biochem. Suppl. 1995, 23, 160–164. [Google Scholar] [CrossRef] [PubMed]
- Mutter, G.L.; Lin, M.C.; Fitzgerald, J.T.; Kum, J.B.; Baak, J.P.A.; Lees, J.A.; Weng, L.P.; Eng, C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst. 2000, 92, 924–930. [Google Scholar] [CrossRef] [PubMed]
- Leslie, K.K.; Thiel, K.W.; Goodheart, M.J.; de Geest, K.; Jia, Y.; Yang, S. Endometrial cancer. Obstet. Gynecol. Clin. N. Am. 2012, 39, 255–268. [Google Scholar] [CrossRef] [PubMed]
- Furness, S.; Roberts, H.; Marjoribanks, J.; Lethaby, A.; Hickey, M.; Farquhar, C. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst. Rev. 2009. [Google Scholar] [CrossRef]
- Cavanagh, D.; Fiorica, J.V.; Hoffman, M.S.; Durfee, J.; Nicosia, S.V. Adenocarcinoma of the endometrium: An institutional review. Cancer Control 1999, 6, 354–360. [Google Scholar] [CrossRef] [PubMed]
- Ryan, A.J.; Susil, B.; Jobling, T.W.; Oehler, M.K. Endometrial cancer. Cell Tissue Res. 2005, 322, 53–61. [Google Scholar] [CrossRef] [PubMed]
- Zagouri, F.; Bozas, G.; Kafantari, E.; Tsiatas, M.; Nikitas, N.; Dimopoulos, M.A.; Papadimitriou, C.A. Endometrial cancer: What is new in adjuvant and molecularly targeted therapy? Obstet. Gynecol. Int. 2010, 2010, 749579. [Google Scholar] [CrossRef] [PubMed]
- Pereira, D.M.; Rodrigues, P.M.; Borralho, P.M.; Rodrigues, C.M. Delivering the promise of miRNA cancer therapeutics. Drug Discov. Today 2013, 18, 282–289. [Google Scholar] [CrossRef] [PubMed]
- McCaskill, J.; Praihirunkit, P.; Sharp, P.M.; Buck, A.H. RNA-mediated degradation of microRNAs: A widespread viral strategy? RNA Biol. 2015, 12, 579–585. [Google Scholar] [CrossRef] [PubMed]
- Sheng, X.; Li, J.; Yang, L.; Chen, Z.; Zhao, Q.; Tan, L.; Zhou, Y.; Li, J. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer. Oncol. Rep. 2014, 32, 277–285. [Google Scholar] [CrossRef] [PubMed]
- Sun, K.X.; Wu, D.D.; Chen, S.; Zhao, Y.; Zong, Z.H. LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway. Apoptosis 2017, 22, 1543–1552. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Zhang, C.; Chen, R.; Xiong, H.; Qiu, F.; Liu, S.; Zhang, M.; Wang, F.; Wang, Y.; Zhou, X.; et al. Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma. Cancer Lett. 2016, 383, 28–40. [Google Scholar] [CrossRef] [PubMed]
- Vennin, C.; Spruyt, N.; Dahmani, F.; Julien, S.; Bertucci, F.; Finetti, P.; Chassat, T.; Bourette, R.P.; Le Bourhis, X.; Adriaenssens, E. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget 2015, 6, 29209–29223. [Google Scholar] [CrossRef] [PubMed]
- Li, Z.; Wei, D.; Yang, C.; Sun, H.; Lu, T.; Kuang, D. Overexpression of long noncoding RNA NEAT1 promotes cell proliferation, invasion and migration in endometrial endometrioid adenocarcinoma. Biomed. Pharmacother. 2016, 84, 244–251. [Google Scholar] [CrossRef] [PubMed]
- Palmieri, G.; Paliogiannis, P.; Sini, M.C.; Manca, A.; Palomba, G.; Doneddu, V.; Tanda, F.; Pascale, M.R.; Cossu, A. Long non-coding RNA CASC2 in human cancer. Crit. Rev. Oncol. Hematol. 2017, 111, 31–38. [Google Scholar] [CrossRef] [PubMed]
- Cabili, M.N.; Trapnell, C.; Goff, L.; Koziol, M.; Tazon-Vega, B.; Regev, A.; Rinn, J.L. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011, 25, 1915–1927. [Google Scholar] [CrossRef] [PubMed]
- Sun, M.Y.; Zhu, J.Y.; Zhang, C.Y.; Zhang, M.; Song, Y.N.; Rahman, K.; Zhang, L.J.; Zhang, H. Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells. Biotechnol. Lett. 2017, 39, 1477–1484. [Google Scholar] [CrossRef] [PubMed]
- Akhmedkhanov, A.; Zeleniuch-Jacquotte, A.; Toniolo, P. Role of exogenous and endogenous hormones in endometrial cancer: Review of the evidence and research perspectives. Ann. N. Y. Acad. Sci. 2001, 943, 296–315. [Google Scholar] [CrossRef] [PubMed]
- Bhan, A.; Hussain, I.; Ansari, K.I.; Kasiri, S.; Bashyal, A.; Mandal, S.S. Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. J. Mol. Biol. 2013, 425, 3707–3722. [Google Scholar] [CrossRef] [PubMed]
- Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M.C.; Hung, T.; Argani, P.; Rinn, J.L.; et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464, 1071–1076. [Google Scholar] [CrossRef] [PubMed]
- He, X.; Bao, W.; Li, X.; Chen, Z.; Che, Q.; Wang, H.; Wan, X.P. The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis. Int. J. Mol. Med. 2014, 33, 325–332. [Google Scholar] [CrossRef] [PubMed]
- Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schütz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; et al. The nuclear receptor superfamily: The second decade. Cell 1995, 83, 835–839. [Google Scholar] [CrossRef]
- Lanz, R.B.; Chua, S.S.; Barron, N.; Söder, B.M.; DeMayo, F.; O’Malley, B.W. Steroid receptor RNA activator stimulates proliferation as well as apoptosis in vivo. Mol. Cell. Biol. 2003, 23, 7163–7176. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Gu, M.; Bo, Y.; Shi, S.; Shan, Y.; Bao, L.; Yiwen, Y. Long non-coding RNA ROR promotes proliferation, migration and chemoresistance of nasopharyngeal carcinoma. Cancer Sci. 2016, 107, 1215–1222. [Google Scholar] [CrossRef] [PubMed]
- Xu, J.; Qian, Y.; Ye, M.; Fu, Z.; Jia, X.; Li, W.; Xu, P.; Lv, M.; Huang, L.; Wang, L.; et al. Distinct expression profile of lncRNA in endometrial carcinoma. Oncol. Rep. 2016, 36, 3405–3412. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.; Malouf, G.G.; Zhang, J.; Zheng, X.; Chen, Y.; Thompson, E.J.; Weinstein, J.N.; Yuan, Y.; Spano, J.P.; Broaddus, R.; et al. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget 2015, 6, 39865–39876. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Chen, X.; Zhang, Y.; Hu, Y.; Shen, X.; Zhu, W. Long non-coding RNA TUG1 promotes endometrial cancer development via inhibiting miR-299 and miR-34a-5p. Oncotarget 2017, 9, 31386–31394. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.; Zhang, J.; Jiang, A.; Liu, Q.; Li, C.; Yang, C.; Xiu, J. Expression profile of long non-coding RNAs is altered in endometrial cancer. Int. J. Clin. Exp. Med. 2015, 8, 5010–5021. [Google Scholar] [PubMed]
- Chen, S.; Chen, X.; Sun, K.X.; Xiu, Y.L.; Liu, B.L.; Feng, M.X.; Sang, X.B.; Zhao, Y. MicroRNA-93 promotes epithelial-mesenchymal transition of endometrial carcinoma cells. PLoS ONE 2016, 11, e0165776. [Google Scholar] [CrossRef] [PubMed]
- Zhai, W.; Li, X.; Wu, S.; Zhang, Y.; Pang, H.; Chen, W. Microarray expression profile of lncRNAs and the upregulated ASLNC04080 lncRNA in human endometrial carcinoma. Int. J. Oncol. 2015, 46, 2125–2137. [Google Scholar] [CrossRef] [PubMed]
- Li, W.; Li, H.; Zhang, L.; Hu, M.; Li, F.; Deng, J.; An, M.; Wu, S.; Ma, R.; Lu, J.; et al. Long non-coding RNA LINC00672 contributes to p53 protein-mediated gene suppression and promotes endometrial cancer chemosensitivity. J. Biol. Chem. 2017, 292, 5801–5813. [Google Scholar] [CrossRef] [PubMed]
- Sun, Y.; Zou, X.; He, J.; Mao, Y. Identification of long non-coding RNAs biomarkers associated with progression of endometrial carcinoma and patient outcomes. Oncotarget 2017, 8, 52604–52613. [Google Scholar] [CrossRef] [PubMed]
- Zhao, L.; Li, Z.; Chen, W.; Zhai, W.; Pan, J.; Pang, H.; Li, X. H19 promotes endometrial cancer progression by modulating epithelial-mesenchymal transition. Oncol. Lett. 2017, 13, 363–369. [Google Scholar] [CrossRef] [PubMed]
- Kaufhold, S.; Bonavida, B. Central role of Snail1 in the regulation of EMT and resistance in cancer: A target for therapeutic intervention. J. Exp. Clin. Cancer Res. 2014, 33, 62. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Wang, D.; Wang, N.; Long, Z.; Ren, X. Long Non-Coding RNA BANCR promotes endometrial cancer cell proliferation and invasion by regulating MMP2 and MMP1 via ERK/MAPK signaling pathway. Cell. Physiol. Biochem. 2016, 40, 644–656. [Google Scholar] [CrossRef] [PubMed]
- Guo, Q.; Qian, Z.; Yan, D.; Li, L.; Huang, L. LncRNA-MEG3 inhibits cell proliferation of endometrial carcinoma by repressing Notch signaling. Biomed. Pharmacother. 2016, 82, 589–594. [Google Scholar] [CrossRef] [PubMed]
- Shang, C.; Lang, B.; Ao, C.N.; Meng, L. Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b. Tumour Biol. 2017, 39. [Google Scholar] [CrossRef] [PubMed]
- Guo, C.; Song, W.Q.; Sun, P.; Jin, L.; Dai, H.Y. LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. J. Biomed. Sci. 2015, 22, 100. [Google Scholar] [CrossRef] [PubMed]
- Qiao, Q.; Li, H. LncRNA FER1L4 suppresses cancer cell proliferation and cycle by regulating PTEN expression in endometrial carcinoma. Biochem. Biophys. Res. Commun. 2016, 478, 507–512. [Google Scholar] [CrossRef] [PubMed]
- Feng, S.; Yao, J.; Chen, Y.; Geng, P.; Zhang, H.; Ma, X.; Zhao, J.; Yu, X. Expression and functional role of reprogramming-related long noncoding RNA (lincRNA-ROR) in Glioma. J. Mol. Neurosci. 2015, 56, 623–630. [Google Scholar] [CrossRef] [PubMed]
- Eades, G.; Wolfson, B.; Zhang, Y.; Li, Q.; Yao, Y.; Zhou, Q. lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol. Cancer Res. 2015, 13, 330–338. [Google Scholar] [CrossRef] [PubMed]
- Hou, P.; Zhao, Y.; Li, Z.; Yao, R.; Ma, M.; Gao, Y.; Zhao, L.; Zhang, Y.; Huang, B.; Lu, J. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014, 5, e1287. [Google Scholar] [CrossRef] [PubMed]
- Gao, S.; Wang, P.; Hua, Y.; Xi, H.; Meng, Z.; Liu, T.; Chen, Z.; Liu, L.M. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Oncotarget 2016, 7, 1608–1618. [Google Scholar] [CrossRef] [PubMed]
- Zhan, H.X.; Wang, Y.; Li, C.; Xu, J.W.; Zhou, B.; Zhu, J.K.; Han, H.F.; Wang, L.; Wang, Y.S.; Hu, S.Y. LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway. Cancer Lett. 2016, 374, 261–271. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, K.; Yan, I.K.; Haga, H.; Patel, T. Modulation of hypoxia-signaling pathways by extracellular linc-RoR. J. Cell Sci. 2014, 127, 1585–1594. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, K.; Yan, I.K.; Kogure, T.; Haga, H.; Patel, T. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio 2014, 4, 458–467. [Google Scholar] [CrossRef] [PubMed]
- Zhou, X.; Gao, Q.; Wang, J.; Zhang, X.; Liu, K.; Duan, Z. Linc-RNA-RoR acts as a “sponge” against mediation of the differentiation of endometrial cancer stem cells by microRNA-145. Gynecol. Oncol. 2014, 133, 333–339. [Google Scholar] [CrossRef] [PubMed]
- Rezaei, M.; Emadi-Baygi, M.; Hoffmann, M.J.; Schulz, W.A.; Nikpour, P. Altered expression of LINC-ROR in cancer cell lines and tissues. Tumour Biol. 2016, 37, 1763–1769. [Google Scholar] [CrossRef] [PubMed]
- Chen, B.J.; Byrne, F.L.; Takenaka, K.; Modesitt, S.C.; Olzomer, E.M.; Mills, J.D.; Farrell, R.; Hoehn, K.L.; Janitz, M. Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer. Gynecol. Oncol. 2017, 147, 654–662. [Google Scholar] [CrossRef] [PubMed]
- Wilczynski, M.; Danielska, J.; Dzieniecka, M.; Szymanska, B.; Wojciechowski, M.; Malinowski, A. Prognostic and clinical significance of miRNA-205 in endometrioid endometrial cancer. PLoS ONE 2016, 11, e0164687. [Google Scholar] [CrossRef] [PubMed]
- Jayaraman, M.; Radhakrishnan, R.; Mathews, C.A.; Yan, M.; Husain, S.; Moxley, K.M.; Song, Y.S.; Dhanasekaran, D.N. Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer. Genes Cancer 2017, 8, 566–576. [Google Scholar] [PubMed]
- He, Z.; Xu, H.; Meng, Y.; Kuang, Y. miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer. Biomed. Pharmacother. 2017, 88, 902–910. [Google Scholar] [CrossRef] [PubMed]
- Ravo, M.; Cordella, A.; Rinaldi, A.; Bruno, G.; Alexandrova, E.; Saggese, P.; Nassa, G.; Giurato, G.; Tarallo, R.; Marchese, G.; et al. Small non-coding RNA deregulation in endometrial carcinogenesis. Oncotarget 2015, 6, 4677–4691. [Google Scholar] [CrossRef] [PubMed]
- Ahsen, M.E.; Boren, T.P.; Singh, N.K.; Misganaw, B.; Mutch, D.G.; Moore, K.N.; Backes, F.J.; McCourt, C.K.; Lea, J.S.; Miller, D.S.; et al. Sparse feature selection for classification and prediction of metastasis in endometrial cancer. BMC Genom. 2017, 27, 233. [Google Scholar] [CrossRef] [PubMed]
- Bahubeshi, A.; Tischkowitz, M.; Foulkes, W.D. miRNA processing and human cancer: DICER1 cuts the mustard. Sci. Transl. Med. 2011, 3. [Google Scholar] [CrossRef] [PubMed]
- Hu, Z.; Zhang, H.; Tang, L.; Lou, M.; Geng, Y. Silencing nc886, a non-coding RNA, induces apoptosis of human endometrial cancer cells-1A in vitro. Med. Sci. Monit. 2017, 16, 1317–1324. [Google Scholar] [CrossRef]
- The Cancer Genome Atlas; National Cancer Institute, National Human Genome Research Institute. Available online: https://cancergenome.nih.gov/ (accessed on 27 March 2018).
- Ihira, K.; Dong, P.; Xiong, Y.; Watari, H.; Konno, Y.; Hanley, S.J.; Noguchi, M.; Hirata, N.; Suizu, F.; Yamada, T.; et al. EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis. Oncotarget 2017, 8, 13509–13520. [Google Scholar] [CrossRef] [PubMed]
- Gong, B.; Yue, Y.; Wang, R.; Zhang, Y.; Jin, Q.; Zhou, X. Overexpression of microRNA-194 suppresses the epithelial-mesenchymal transition in targeting stem cell transcription factor Sox3 in endometrial carcinoma stem cells. Tumor Biol. 2017, 39. [Google Scholar] [CrossRef] [PubMed]
- Chen, H.X.; Xu, X.X.; Tan, B.Z.; Zhang, Z.; Zhou, X.D. MicroRNA-29b inhibits angiogenesis by targeting VEGFA through the MAPK/ERK and PI3K/Akt signaling pathways in endometrial carcinoma. Cell. Physiol. Biochem. 2017, 41, 933–946. [Google Scholar] [CrossRef] [PubMed]
- Alowayed, N.; Salker, M.S.; Zeng, N.; Singh, Y.; Lang, F. LEFTY2 controls migration of human endometrial cancer cells via focal adhesion kinase activity (FAK) and miRNA-200a. Cell. Physiol. Biochem. 2016, 39, 815–826. [Google Scholar] [CrossRef] [PubMed]
- Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis 2010, 31, 27–36. [Google Scholar] [CrossRef] [PubMed]
- Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358, 1148–1159. [Google Scholar] [CrossRef] [PubMed]
- Hosseini, E.S.; Meryet-Figuiere, M.; Sabzalipoor, H.; Kashani, H.H.; Nikzad, H.; Asemi, Z. Dysregulated expression of long noncoding RNAs in gynecologic cancers. Mol. Cancer 2017, 16, 107. [Google Scholar] [CrossRef] [PubMed]
- Ivanga, M.; Labrie, Y.; Calvo, E.; Belleau, P.; Martel, C.; Luu-The, V.; Morissette, J.; Labrie, F.; Durocher, F. Temporal analysis of E2 transcriptional induction of PTP and MKP and downregulation of IGF-I pathway key components in the mouse uterus. Physiol. Genom. 2007, 29, 13–23. [Google Scholar] [CrossRef] [PubMed]
NcRNA | Type of ncRNA Regulation/Interaction | Type of EC Regulation/Pathway Interaction | In Vivo or In Vitro Assay or Humans | Reference |
---|---|---|---|---|
LncRNA OVAL | down and upregulation | downregulation in type II EC and upregulation in type I EC | In vitro assay from EC tissue | [6] |
LncRNA MALAT-1 | downregulation/interaction with miR-200 | downregulation in EC through miR-200 | In vitro assay from EC tissue, xenograft tumor model | [25] |
LncRNA TUG1 | interaction with miR-299/miR-34a-5p | promotion of EC via miR-299 and miR-34a-5p inhibition | In vivo mouse assay, in vitro assay from EC tissue and HEC-1-A cell lines | [40] |
LncRNAs HOTAIR | upregulation | downregulation in Cisplatin-Resistant Ishikawa Cells (CRIC) and parental IC treated with cisplatin; up-regulation with EC tumor grade increase | In vitro assay CRIC cells; in vitro assay from EC tissue | [30,34] |
LncRNAs H19 | upregulation | upregulation with EC tumor grade increase and other features associated with poor prognosis | In vitro assay from EC tissues and EC cell line | [46] |
LncRNAs SRA | upregulation | upregulation regardless of histological tumor grade | In vitro assay from EC tissues | [36] |
LncRNA BANCR | upregulation | promotion of EE cell proliferation and invasion by MMP2 and MMP1 regulation via ERK–MAPK signaling pathway in type 1 EC | In vitro assay from EC tissues | [48] |
LncRNAs panel (e.g., KIAA0087, RP11-501O2, FAM212B-AS1, LOC102723552, RP11-140I24 and RP11-600K151) | differential regulation/interaction with 188 mRNAs | differential expression in type I EC | In vitro assay from EC tissues | [38] |
LncRNA CASC2 | downregulation | potential role as a tumor suppressor | In vitro assay from EC tissues | [29] |
LncRNA ASLNC04080 | upregulation | upregulation in 22–24 EC tissues and HEC-1-B cell line | In vitro assay from EC tissues and EC cell line | [43] |
LncRNAs panel (e.g., FLJ27354, RP11-275I14.4, VIM-AS1, CTB-51J22.1 and RP11-229P13.20) | up and downregulation | potential biomarkers of Uterine Corpus (UCEC) | In vitro assay from EC tissues | [45] |
LncRNA TUSC7 | downregulation | related to EC tumorigenesis and progression | In vitro assay from EC tissues | [50] |
LncRNA FER1L4 | downregulation | decrease of cell proliferation in FER1L4-overexpressing cells | In vitro assay from EC cell line | [52] |
LncRNA NEAT | upregulation | increase of Nuclear Enriched Abundant Transcript 1 (NEAT1) in EC | In vitro assay from EC tissues and cell lines | [27] |
LncRNA MEG3 | downregulation | anti-proliferative role in EC by repressing Notch signaling pathway | In vitro assay from EC tissues and cell lines | [49] |
LncRNA GAS5/miR-103 | downregulation / inhibition of miRNA-103 expression | tumor suppressor | In vitro assay from EC tissues and cell lines | [51] |
LincRNA LINC00958 | upregulation | increase of LINC00958 in EC | In vitro assay from EC tissues | [62] |
LincRNA LINC00672 | downregulation | downregulation during EC development | In vitro assay from EC tissues | [44] |
NcRNA Nc886 | upregulation | upregulation of nc886 in EC late phases, compared to early stages and Normal Endometrial Tissues (NET) | In vitro assay from EC tissues | [68] |
miRNA-93 | upregulation | over-expression associated to cell migration and invasion | In vitro assay from EC tissues and cell lines | [42] |
miRNA-205 | upregulation | prognostic marker associated with better overall survival | In vitro assay from EC tissues | [63] |
miRNA-944 | upregulation | over-expression in EC tissues compared to NET | In vitro assay from EC tissues | [65] |
miRNA-29b | miRNA-29b/MAPK/ERK and PI3K/Akt signaling pathways | inhibition of angiogenesis by targeting VEGFA through MAPK/ERK and PI3K/Akt signaling | In vitro assay from EC tissues and cell lines | [73] |
miRNA-145 | upregulation | upregulation of miR-145 lead to downregulation of linc-RoR7Dicer | In vitro assay from EC tissues | [60] |
miRNA-361 | miR-361/twist signaling and miR-361/let-7b downregulation | lower let-7b, twist signaling and miR-361 are associated with worse patient outcome | In vitro assay from EC tissues | [71] |
miRNA-194 | downregulation | downregulation associated to EC poor prognosis | In vitro assay from EC tissues and cell lines | [73] |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vallone, C.; Rigon, G.; Gulia, C.; Baffa, A.; Votino, R.; Morosetti, G.; Zaami, S.; Briganti, V.; Catania, F.; Gaffi, M.; et al. Non-Coding RNAs and Endometrial Cancer. Genes 2018, 9, 187. https://doi.org/10.3390/genes9040187
Vallone C, Rigon G, Gulia C, Baffa A, Votino R, Morosetti G, Zaami S, Briganti V, Catania F, Gaffi M, et al. Non-Coding RNAs and Endometrial Cancer. Genes. 2018; 9(4):187. https://doi.org/10.3390/genes9040187
Chicago/Turabian StyleVallone, Cristina, Giuliano Rigon, Caterina Gulia, Alberto Baffa, Raffaella Votino, Giulia Morosetti, Simona Zaami, Vito Briganti, Francesco Catania, Marco Gaffi, and et al. 2018. "Non-Coding RNAs and Endometrial Cancer" Genes 9, no. 4: 187. https://doi.org/10.3390/genes9040187